FLAURA2: Safety data support osimertinib plus chemotherapy as a beneficial frontline therapy for patients with EGFR-mutated advanced NSCLC

ELCC 2024

Lung, Respiratory and Thoracic Cancer

FLAURA2: Frontline osimertinib plus chemotherapy in patients with EGFR-mutated advanced NSCLC

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC

ELCC 2024

Lung, Respiratory and Thoracic Cancer

FLAURA2: Osimertinib plus chemotherapy provides long-term benefits in post-progression outcomes versus osimertinib alone in EGFR-mutated advanced NSCLC

ESMO 2024

Lung, Respiratory and Thoracic Cancer

MARIPOSA-2: OS data continued to favor amivantamab plus chemotherapy over chemotherapy alone in patients with EGFR-mutated NSCLC

ELCC 2024

Lung, Respiratory and Thoracic Cancer

MARIPOSA-2: Improved post-progression outcomes with amivantamab plus chemotherapy in EGFR-mutated advanced NSCLC

ESMO 2024

Lung, Respiratory and Thoracic Cancer

MARIPOSA: Amivantamab plus lazertinib reduced the incidence of acquired MET and EGFR resistance alterations versus osimertinib in patients with NSCLC

Lung, Respiratory and Thoracic Cancer

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Lancet Oncol

Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM, INSIGHT 2 investigators

doi: 10.1016/S1470-2045(24)00270-5

Lung, Respiratory and Thoracic Cancer

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01

Eur J Cancer

Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M

doi: 10.1016/j.ejca.2024.115117

ELCC 2024

Lung, Respiratory and Thoracic Cancer

Related content

FLAURA2: Frontline osimertinib plus chemotherapy in patients with EGFR-mutated advanced NSCLC

Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC

FLAURA2: Osimertinib plus chemotherapy provides long-term benefits in post-progression outcomes versus osimertinib alone in EGFR-mutated advanced NSCLC

MARIPOSA-2: OS data continued to favor amivantamab plus chemotherapy over chemotherapy alone in patients with EGFR-mutated NSCLC

MARIPOSA-2: Improved post-progression outcomes with amivantamab plus chemotherapy in EGFR-mutated advanced NSCLC

MARIPOSA: Amivantamab plus lazertinib reduced the incidence of acquired MET and EGFR resistance alterations versus osimertinib in patients with NSCLC

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01

EMPOWER-Lung 3: Frontline cemiplimab combination improves PRO versus chemotherapy in patients with advanced NSCLC